|
1
|
Armitage JO, Gascoyne RD, Lunning MA and
Cavalli F: Non-Hodgkin lymphoma. Lancet. 390:298–310. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guerard EJ and Bishop MR: Overview of
non-Hodgkin's lymphoma. Dis Mon. 58:208–218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martelli M, Ferreri AJ, Agostinelli C, Di
Rocco A, Pfreundschuh M and Pileri SA: Diffuse large B-cell
lymphoma. Crit Rev Oncol Hematol. 87:146–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu Y and Barta SK: Diffuse large B-cell
lymphoma: 2019 Update on diagnosis, risk stratification, and
treatment. Am J Hematol. 94:604–616. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Winder SJ and Walsh MP: Smooth muscle
calponin. Inhibition of actomyosin MgATPase and regulation by
phosphorylation. J Biol Chem. 265:10148–10155. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Winder SJ, Walsh MP, Vasulka C and Johnson
JD: Calponin-calmodulin interaction: Properties and effects on
smooth and skeletal muscle actin binding and actomyosin ATPases.
Biochemistry. 32:13327–13333. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kake T, Kimura S, Takahashi K and Maruyama
K: Calponin induces actin polymerization at low ionic strength and
inhibits depolymerization of actin filaments. Biochem J.
312:587–592. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferhat L, Esclapez M, Represa A, Fattoum
A, Shirao T and Ben-Ari Y: Increased levels of acidic calponin
during dendritic spine plasticity after pilocarpine-induced
seizures. Hippocampus. 13:845–858. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Flemming A, Huang QQ, Jin JP, Jumaa H and
Herzog S: A conditional knockout mouse model reveals that
calponin-3 is dispensable for early B cell development. PLoS
One. 10:e01283852015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shibukawa Y, Yamazaki N, Kumasawa K,
Daimon E, Tajiri M, Okada Y, Ikawa M and Wada Y: Calponin 3
regulates actin cytoskeleton rearrangement in trophoblastic cell
fusion. Mol Biol Cell. 21:3973–3984. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia L, Yue Y, Li M, Zhang YN, Zhao L, Lu
W, Wang X and Xie X: CNN3 acts as a potential oncogene in cervical
cancer by affecting RPLP1 mRNA expression. Sci Rep. 10:24272020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nair VA, Al-Khayyal NA, Sivaperumal S and
Abdel-Rahman WM: Calponin 3 promotes invasion and drug resistance
of colon cancer cells. World J Gastrointest Oncol. 11:971–982.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hong KS, Kim H, Kim SH, Kim M and Yoo J:
Calponin 3 regulates cell invasion and doxorubicin resistance in
gastric cancer. Gastroenterol Res Pract. 2019:30249702019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsuji T, Maeda Y, Kita K, Murakami K, Saya
H, Takemura H, Inaki N, Oshima M and Oshima H: FOXO3 is a latent
tumor suppressor for FOXO3-positive and cytoplasmic-type gastric
cancer cells. Oncogene. 40:3072–3086. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shukla S, Bhaskaran N, Maclennan GT and
Gupta S: Deregulation of FoxO3a accelerates prostate cancer
progression in TRAMP mice. Prostate. 73:1507–1517. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Blake DC Jr, Mikse OR, Freeman WM and
Herzog CR: FOXO3a elicits a pro-apoptotic transcription program and
cellular response to human lung carcinogen nicotine-derived
nitrosaminoketone (NNK). Lung Cancer. 67:37–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng X, Rui H, Liu Y and Dong J:
Proliferation and apoptosis of B-cell lymphoma cells under targeted
regulation of FOXO3 by miR-155. Mediterr J Hematol Infect Dis.
12:e20200732020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bi C and Wang G: LINC00472 suppressed by
ZEB1 regulates the miR-23a-3p/FOXO3/BID axis to inhibit the
progression of pancreatic cancer. J Cell Mol Med. 25:8312–8328.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu S, Yu Y, Zhang W, Yuan W, Zhao N, Li Q,
Cui Y, Wang Y, Li W, Sun Y and Liu T: FOXO3a promotes gastric
cancer cell migration and invasion through the induction of
cathepsin L. Oncotarget. 7:34773–34784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu C, Ni Z, Li BS, Yong X, Yang X, Zhang
JW, Zhang D, Qin Y, Jie MM, Dong H, et al: hTERT promotes the
invasion of gastric cancer cells by enhancing FOXO3a ubiquitination
and subsequent ITGB1 upregulation. Gut. 66:31–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bouzeyen R, Haoues M, Barbouche MR, Singh
R and Essafi M: FOXO3 transcription factor regulates IL-10
expression in mycobacteria-infected macrophages, tuning their
polarization and the subsequent adaptive immune response. Front
Immunol. 10:29222019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Benayoun BA, Caburet S and Veitia RA:
Forkhead transcription factors: Key players in health and disease.
Trends Genet. 27:224–232. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Anderson MJ, Viars CS, Czekay S, Cavenee
WK and Arden KC: Cloning and characterization of three human
forkhead genes that comprise an FKHR-like gene subfamily. Genomics.
47:187–199. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Ao X, Ding W, Ponnusamy M, Wu W,
Hao X, Yu W, Wang Y, Li P and Wang J: Critical role of FOXO3a in
carcinogenesis. Mol Cancer. 17:1042018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ai B, Kong X, Wang X, Zhang K, Yang X,
Zhai J, Gao R, Qi Y, Wang J, Wang Z and Fang Y: LINC01355
suppresses breast cancer growth through FOXO3-mediated
transcriptional repression of CCND1. Cell Death Dis. 10:5022019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marlow LA, von Roemeling CA, Cooper SJ,
Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV, Tun
HW, et al: Foxo3a drives proliferation in anaplastic thyroid
carcinoma through transcriptional regulation of cyclin A1: A
paradigm shift that impacts current therapeutic strategies. J Cell
Sci. 125:4253–4263. 2012.PubMed/NCBI
|
|
29
|
Yamamura Y, Lee WL, Inoue K, Ida H and Ito
Y: RUNX3 cooperates with FoxO3a to induce apoptosis in gastric
cancer cells. J Biol Chem. 281:5267–5276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Obexer P, Geiger K, Ambros PF, Meister B
and Ausserlechner MJ: FKHRL1-mediated expression of Noxa and Bim
induces apoptosis via the mitochondria in neuroblastoma cells. Cell
Death Differ. 14:534–547. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vandenberg CJ, Motoyama N and Cory S:
FoxO3 suppresses Myc-driven lymphomagenesis. Cell Death Dis.
6:e20462016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu R and Jin JP: Calponin isoforms CNN1,
CNN2 and CNN3: Regulators for actin cytoskeleton functions in
smooth muscle and non-muscle cells. Gene. 585:143–153. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
She Y, Li C, Jiang T, Lei S, Zhou S, Shi H
and Chen R: Knockdown of CNN3 impairs myoblast proliferation,
differentiation, and protein synthesis via the mTOR pathway. Front
Physiol. 12:6592722021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Daimon E, Shibukawa Y and Wada Y: Calponin
3 regulates stress fiber formation in dermal fibroblasts during
wound healing. Arch Dermatol Res. 305:571–584. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dai F, Luo F, Zhou R, Zhou Q, Xu J, Zhang
Z, Xiao J and Song L: Calponin 3 is associated with poor prognosis
and regulates proliferation and metastasis in osteosarcoma. Aging
(Albany NY). 12:14037–14049. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang C, Zhu S, Feng W and Chen X: Calponin
3 suppresses proliferation, migration and invasion of non-small
cell lung cancer cells. Oncol Lett. 22:6342021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Malumbres M and Barbacid M: To cycle or
not to cycle: A critical decision in cancer. Nat Rev Cancer.
1:222–231. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sherr CJ and Roberts JM: Living with or
without cyclins and cyclin-dependent kinases. Genes Dev.
18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hengartner MO: Apoptosis: Corralling the
corpses. Cell. 104:325–328. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schneider P and Tschopp J: Apoptosis
induced by death receptors. Pharm Acta Helv. 74:281–286. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ghobrial IM, Witzig TE and Adjei AA:
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin.
55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Amé JC, Spenlehauer C and de Murcia G: The
PARP superfamily. Bioessays. 26:882–893. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Koh DW, Dawson TM and Dawson VL: Mediation
of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res.
52:5–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tewari M, Quan LT, O'Rourke K, Desnoyers
S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM:
Yama/CPP32 beta, a mammalian homolog of CED-3, is a
CrmA-inhibitable protease that cleaves the death substrate
poly(ADP-ribose) polymerase. Cell. 81:801–809. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
van Engeland M, Nieland LJ, Ramaekers FC,
Schutte B and Reutelingsperger CP: Annexin V-affinity assay: A
review on an apoptosis detection system based on phosphatidylserine
exposure. Cytometry. 31:1–9. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rosenwald A, Wright G, Chan WC, Connors
JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland
EB, Giltnane JM, et al: The use of molecular profiling to predict
survival after chemotherapy for diffuse large-B-cell lymphoma. N
Engl J Med. 346:1937–1947. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lenz G, Wright G, Dave SS, Xiao W, Powell
J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, et al: Stromal gene
signatures in large-B-cell lymphomas. N Engl J Med. 359:2313–2323.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Scott DW, Mottok A, Ennishi D, Wright GW,
Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta
P, et al: Prognostic significance of diffuse large B-cell lymphoma
cell of origin determined by digital gene expression in
formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol.
33:2848–2856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sehn LH and Salles G: Diffuse large B-cell
lymphoma. N Engl J Med. 384:842–858. 2021. View Article : Google Scholar : PubMed/NCBI
|
